Skip to main content
Loading

Aspiro Therapeutics

February 10, 2025
Aspiro Therapeutics
Aspiro Therapeutics is on a mission to revolutionize treatment for obstructive lung diseases by mimicking the protective power of CC16, a natural lung protein vital for healthy breathing. We are focused on developing advanced, disease-modifying therapies that target the underlying mechanisms of conditions like asthma and COPD, going beyond symptom relief to alter the natural course of these diseases. By harnessing the protective properties of CC16, we aim to restore lung function and prevent disease progression, offering patients safer and more effective treatment options. Through innovation and a commitment to improving respiratory care, we strive to make a lasting impact on the lives of those affected by obstructive lung diseases.
Speakers
James Lovgren, Chief Executive Officer & Co-Founder - Aspiro Therapeutics
View all 2025 Program
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP